Alex Zhavoronkov and Feng Ren, Insilico co-CEOs

As their first clin­i­cal da­ta test looms, glob­al AI play­er In­sil­i­co bumps up a GSK vet to co-CEO in charge of de­vel­op­ment

Days af­ter top­ping up In­sil­i­co Med­i­cine’s cash re­serves with a $60 mil­lion round, the glob­al AI play­er is re­design­ing its ex­ec­u­tive struc­ture with an un­usu­al twist as it shifts from pure drug de­sign and dis­cov­ery and builds out the pipeline with clin­i­cal stage as­sets.

A lit­tle more than a year af­ter step­ping in as the CSO, Feng Ren, the Har­vard grad and GSK vet with ex­pe­ri­ence in Philadel­phia and Shang­hai, is step­ping up to a co-CEO role. He’ll be in charge of the de­vel­op­ment work, as they start test­ing more of their drugs in hu­mans and put their promise of a more ef­fi­cient ap­proach to drug hunt­ing to the ul­ti­mate test.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.